Clinical Trial Update: Rivaroxaban for Treatment of Patients With Suspected or Confirmed Heparin-Induced Thrombocytopenia [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial evaluating rivaroxaban for treatment of suspected or confirmed heparin-induced thrombocytopenia has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heparin-induced Thrombocytopenia

Drugs mentioned

• Rivaroxaban (Xarelto) (rivaroxaban)

Snippet

Sponsor: McMaster University | Conditions: Heparin-induced Thrombocytopenia | Phase 3 | Status: TERMINATED